Relay Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
RLAY$20.39+9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $124,287 | $143,736 |
| Investments | 657,036 | 606,350 |
| Prepaid expenses | 17,348 | 16,702 |
| Other current assets | 10,533 | 3,315 |
| Total current assets | 809,204 | 770,103 |
| Property and equipment, net | 5,911 | 10,901 |
| Operating lease assets | 51,762 | 57,969 |
| Restricted cash | 2,119 | 2,707 |
| Intangible asset | 2,300 | 2,300 |
| Total assets | $871,296 | $843,980 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $14,097 | $9,211 |
| Accrued expenses | 21,236 | 14,890 |
| Operating lease liabilities | 5,727 | 4,964 |
| Deferred revenue | 7,679 | — |
| Other current liabilities | 1,990 | 1,204 |
| Total current liabilities | 50,729 | 30,269 |
| Operating lease liabilities, net of current portion | 42,775 | 48,502 |
| Contingent consideration liability | — | 13,206 |
| Total liabilities | 93,504 | 91,977 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued and outstanding as of December 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.001 par value; 300,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 167,755,715 and 127,462,409 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 168 | 127 |
| Additional paid-in capital | 2,516,905 | 2,152,654 |
| Accumulated other comprehensive loss | (991) | (196) |
| Accumulated deficit | (1,738,290) | (1,400,582) |
| Total stockholders’ equity | 777,792 | 752,003 |
| Total liabilities and stockholders’ equity | $871,296 | $843,980 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.